Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cosyntropin (Cortrosyn) vs Etelcalcetide (Parsabiv)
An educational, source-based comparison of Cosyntropin (Cortrosyn) and Etelcalcetide (Parsabiv) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic peptide containing the first 24 amino acids of ACTH — retains full corticotropic activity. Stimulates adrenal cortisol release for diagnostic testing.
- Primary and secondary adrenal insufficiency diagnosis
- • FDA-approved.
- • Single diagnostic dose; very well tolerated.
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
- Secondary hyperparathyroidism in adults on chronic hemodialysis
- • FDA-approved.
- • Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Cosyntropin (Cortrosyn) vs Etelcalcetide (Parsabiv) — Key differences
- Class: Cosyntropin (Cortrosyn) is classified as Diagnostic · Endocrine, while Etelcalcetide (Parsabiv) is Calcium-Sensing Receptor Agonist · Endocrine.
- Primary research focus: Cosyntropin (Cortrosyn) — primary and secondary adrenal insufficiency diagnosis; Etelcalcetide (Parsabiv) — secondary hyperparathyroidism in adults on chronic hemodialysis.
- Tag: FDA-Approved · Diagnostic vs FDA-Approved · Endocrine.